Testing effectiveness (Phase 2)Study completedNCT04380805
What this trial is testing
AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer
Who this might be right for
Recurrent Cervical CancerMetastatic Cervical Cancer
Akeso 30